FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1504964919> ?p ?o ?g. }

• W1504964919 endingPage "2236" @default.
• W1504964919 startingPage "2229" @default.
• W1504964919 abstract "Abstract The CD33 antigen, identified by murine monoclonal antibody anti-MY9, is expressed by clonogenic leukemic cells from almost all patients with acute myeloid leukemia; it is also expressed by normal myeloid progenitor cells. Twelve consecutive patients with de novo acute myeloid leukemia received myeloablative therapy followed by infusion of autologous marrow previously treated in vitro with anti-MY9 and complement. Anti-MY9 and complement treatment eliminated virtually all committed myeloid progenitors (colony-forming unit granulocyte- macrophage) from the autografts. Nevertheless, in the absence of early relapse of leukemia, all patients showed durable trilineage engraftment. The median interval post bone marrow transplantation (BMT) required to achieve an absolute neutrophil count greater than 500/microL was 43 days (range, 16 to 75), to achieve a platelet count greater than 20,000/microL without transfusion was 92 days (range, 35 to 679), and to achieve red blood cell transfusion independence was 105 days (range, 37 to 670). At the time of BM harvest, 10 patients were in second remission, one patient was in first remission, and one patient was in third remission. Eight patients relapsed 3 to 18 months after BMT. Four patients transplanted in second remission remain disease-free 34+, 37+, 52+, and 57+ months after BMT. There was no treatment-related mortality. Early engraftment was significantly delayed in patients receiving CD33-purged autografts compared with concurrently treated patients receiving CD9/CD10-purged autografts for acute lymphoblastic leukemia or patients receiving CD6-purged allografts from HLA- compatible sibling donors. In contrast, both groups of autograft patients required a significantly longer time to achieve neutrophil counts greater than 500/microL and greater than 1,000/microL than did patients receiving normal allogeneic marrow. CD33(+)-committed myeloid progenitor cells thus appear to play an important role in the early phase of hematopoietic reconstitution after BMT. However, our results also show that human marrow depleted of CD33+ cells can sustain durable engraftment after myeloablative therapy, and provide further evidence that the CD33 antigen is absent from the human pluripotent hematopoietic stem cell." @default.
• W1504964919 created "2016-06-24" @default.
• W1504964919 creator A5008718116 @default.
• W1504964919 creator A5017719443 @default.
• W1504964919 creator A5019128517 @default.
• W1504964919 creator A5032464400 @default.
• W1504964919 creator A5037942629 @default.
• W1504964919 creator A5039503690 @default.
• W1504964919 creator A5055209325 @default.
• W1504964919 creator A5064257609 @default.
• W1504964919 creator A5068050082 @default.
• W1504964919 creator A5076249181 @default.
• W1504964919 creator A5090485287 @default.
• W1504964919 date "1992-05-01" @default.
• W1504964919 modified "2023-10-13" @default.
• W1504964919 title "Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia" @default.
• W1504964919 cites W102480758 @default.
• W1504964919 cites W139860964 @default.
• W1504964919 cites W1481564836 @default.
• W1504964919 cites W1490499251 @default.
• W1504964919 cites W1533557093 @default.
• W1504964919 cites W1565641005 @default.
• W1504964919 cites W1573785776 @default.
• W1504964919 cites W1588212475 @default.
• W1504964919 cites W1776520887 @default.
• W1504964919 cites W1823520599 @default.
• W1504964919 cites W1966144382 @default.
• W1504964919 cites W1975188468 @default.
• W1504964919 cites W1977404622 @default.
• W1504964919 cites W1979300931 @default.
• W1504964919 cites W1995440539 @default.
• W1504964919 cites W2001923586 @default.
• W1504964919 cites W2004406962 @default.
• W1504964919 cites W2020290800 @default.
• W1504964919 cites W2027802649 @default.
• W1504964919 cites W2036479586 @default.
• W1504964919 cites W2067131989 @default.
• W1504964919 cites W2087934471 @default.
• W1504964919 cites W2137696432 @default.
• W1504964919 cites W2146018570 @default.
• W1504964919 cites W2148855592 @default.
• W1504964919 cites W2249401906 @default.
• W1504964919 cites W2266841241 @default.
• W1504964919 cites W2277390673 @default.
• W1504964919 cites W2294409256 @default.
• W1504964919 cites W2300654763 @default.
• W1504964919 cites W232095477 @default.
• W1504964919 cites W2339392195 @default.
• W1504964919 cites W2345454632 @default.
• W1504964919 cites W2396527347 @default.
• W1504964919 cites W2400938719 @default.
• W1504964919 cites W2409849732 @default.
• W1504964919 cites W2410218008 @default.
• W1504964919 cites W2412055789 @default.
• W1504964919 cites W2412431833 @default.
• W1504964919 cites W2417759139 @default.
• W1504964919 cites W2436656101 @default.
• W1504964919 cites W2462871550 @default.
• W1504964919 cites W2796700885 @default.
• W1504964919 cites W3147784190 @default.
• W1504964919 cites W338459411 @default.
• W1504964919 cites W2410277625 @default.
• W1504964919 doi "https://doi.org/10.1182/blood.v79.9.2229.2229" @default.
• W1504964919 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1571539" @default.
• W1504964919 hasPublicationYear "1992" @default.
• W1504964919 type Work @default.
• W1504964919 sameAs 1504964919 @default.
• W1504964919 citedByCount "96" @default.
• W1504964919 countsByYear W15049649192012 @default.
• W1504964919 countsByYear W15049649192013 @default.
• W1504964919 countsByYear W15049649192014 @default.
• W1504964919 countsByYear W15049649192015 @default.
• W1504964919 countsByYear W15049649192017 @default.
• W1504964919 countsByYear W15049649192020 @default.
• W1504964919 countsByYear W15049649192021 @default.
• W1504964919 countsByYear W15049649192022 @default.
• W1504964919 crossrefType "journal-article" @default.
• W1504964919 hasAuthorship W1504964919A5008718116 @default.
• W1504964919 hasAuthorship W1504964919A5017719443 @default.
• W1504964919 hasAuthorship W1504964919A5019128517 @default.
• W1504964919 hasAuthorship W1504964919A5032464400 @default.
• W1504964919 hasAuthorship W1504964919A5037942629 @default.
• W1504964919 hasAuthorship W1504964919A5039503690 @default.
• W1504964919 hasAuthorship W1504964919A5055209325 @default.
• W1504964919 hasAuthorship W1504964919A5064257609 @default.
• W1504964919 hasAuthorship W1504964919A5068050082 @default.
• W1504964919 hasAuthorship W1504964919A5076249181 @default.
• W1504964919 hasAuthorship W1504964919A5090485287 @default.
• W1504964919 hasBestOaLocation W15049649191 @default.
• W1504964919 hasConcept C10205521 @default.
• W1504964919 hasConcept C126322002 @default.
• W1504964919 hasConcept C141071460 @default.
• W1504964919 hasConcept C176290653 @default.
• W1504964919 hasConcept C203014093 @default.
• W1504964919 hasConcept C2776863199 @default.
• W1504964919 hasConcept C2778461978 @default.
• W1504964919 hasConcept C2778729363 @default.
• W1504964919 hasConcept C2779282312 @default.

• next